Literature DB >> 22088817

The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis.

Sébastien Gaujoux1, Laura Tang, David Klimstra, Mithat Gonen, Murray F Brennan, Michael D'Angelica, Ronald DeMatteo, Yuman Fong, William Jarnagin, Peter J Allen.   

Abstract

INTRODUCTION: Cystic pancreatic endocrine neoplasms (CPENs) are uncommon tumors with uncertain disease biology and ill-defined diagnostic features.
METHODS: A prospectively maintained pancreatic cyst registry was queried, and 31 cases of CPEN that were resected between 1995 and 2010 were identified. Patient and lesion characteristics were detailed and compared with resected non-PEN cystic lesions. Recurrence and survival outcome were compared with 31 noncystic PENs matched for functional status, differentiation, size, World Health Organization classification, grade, and presence of metastases.
RESULTS: During the study period, CPENs accounted for 7% of resected pancreatic cysts (31/469) and 12% of resected PENs (31/255). CPENs were primarily sporadic (94%), solitary (87%), nonfunctioning (100%), and incidentally discovered (68%). The median diameter was 2.1 cm (range, 0.9-6.2 cm), and preoperative imaging identified septations in 29%, a solid component in 26%, and cyst wall enhancement or a characteristic hypervascular rim in 45% of cases. Preoperative imaging and/or cytology suggested the diagnosis of CPEN in 61%. Compared with resected nonendocrine cystic lesions, CPEN were less frequently symptomatic, less likely to contain septations, and smaller. Compared with matched noncystic PENs, CPENs had comparable demographic, radiologic, and pathologic features and statistically similar long-term outcome (5-year disease-free survival: CPEN: 100% vs PEN: 86%, P = .947).
CONCLUSION: In this study, CPENs were primarily asymptomatic small lesions that could be characterized in the majority of cases by cyst wall enhancement on preoperative imaging and/or cytologic assessment. No significant difference in recurrence or survival outcome was identified between cystic and noncystic PENs. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22088817     DOI: 10.1016/j.surg.2011.09.037

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection.

Authors:  Jon M Gerry; George A Poultsides
Journal:  Dig Dis Sci       Date:  2017-04-18       Impact factor: 3.199

Review 2.  Therapeutic Approach to Cystic Neoplasms of the Pancreas.

Authors:  Mohammad Al Efishat; Peter J Allen
Journal:  Surg Oncol Clin N Am       Date:  2016-04       Impact factor: 3.495

Review 3.  Pancreatic Cysts and Guidelines.

Authors:  James J Farrell
Journal:  Dig Dis Sci       Date:  2017-05-20       Impact factor: 3.199

Review 4.  Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions.

Authors:  James J Farrell
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

Review 5.  Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options.

Authors:  Tanima Jana; Jennifer Shroff; Manoop S Bhutani
Journal:  J Carcinog       Date:  2015-03-14

6.  The rare case of a cystic pancreatic neuroendocrine tumor.

Authors:  Tarun Kumar; Brijnandan Gupta; Prasenjit Das; Kumble S Madhusudhan
Journal:  Autops Case Rep       Date:  2020-06-05

Review 7.  Differential Diagnosis of Cystic Pancreatic Lesions Including the Usefulness of Biomarkers.

Authors:  Philippe Lévy; Vinciane Rebours
Journal:  Viszeralmedizin       Date:  2015-02

Review 8.  Pancreatic Cystic Lesions: Pathogenesis and Malignant Potential.

Authors:  Antoinette J Pusateri; Somashekar G Krishna
Journal:  Diseases       Date:  2018-06-13

9.  A single-center experience with pancreatic cystic neuroendocrine tumors.

Authors:  Ange Khalil; Jacques Ewald; Ugo Marchese; Aurélie Autret; Jonathan Garnier; Patricia Niccoli; Gilles Piana; Flora Poizat; Marc Giovannini; Jean-Robert Delpero; Olivier Turrini
Journal:  World J Surg Oncol       Date:  2020-08-15       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.